Aristea Therapeutics, a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, said that due to safety findings in the ongoing Phase 2 clinical trials, it has discontinued the RIST4721 development program in order to protect patient safety.  The board of directors has also determined, after careful, and extensive consideration of a range of strategic alternatives, that the appropriate business decision is to undertake...